The most common experimental dose in animal studies (Sikiric et al.) is 10 g/kg/day intraperitoneally or orally in rats
The efficacy of subcutaneous semaglutide was established in the phase III SUSTAIN program (SUSTAIN 15 and 7), in which significant reductions in mean glycated hemoglobin (HbA 1c ) and body weight were demonstrated against placebo and a variety of active comparators in multiple patient groups with T2D [26,27,28,29,30,31,32,33]
Questions to Ask Your Doctor If youre using a GLP-1 medication, its worth having a conversation about how to optimize your results
Medically reviewed by Missy Zammichieli, DNP, APRN, FNP-BC Updated March 24, 2026 Book Consultation WHAT IS PT-141
To reduce the risk of serious parasitic disease, several preventative treatments and screening tests have been developed